ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

XERS Xeris Biopharma Holdings Inc

2.13
-0.05 (-2.29%)
19 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Xeris Biopharma Holdings Inc NASDAQ:XERS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -2.29% 2.13 2.10 2.17 2.1914 2.10 2.18 871,609 01:00:00

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

02/04/2024 12:00pm

Business Wire


Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart


From Mar 2024 to Jun 2024

Click Here for more Xeris Biopharma Charts.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 11:00 am Eastern Time. To access the presentation, please visit “Events” on the investor relations page of the Company’s website at www.xerispharma.com.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

Investor Contact

Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com

1 Year Xeris Biopharma Chart

1 Year Xeris Biopharma Chart

1 Month Xeris Biopharma Chart

1 Month Xeris Biopharma Chart

Your Recent History

Delayed Upgrade Clock